Definium Therapeutics, Inc. 4

CEO Robert Barrow received an award of 750,000 Definium Therapeutics (DFTX) common shares as a performance share unit tranche subject to future vesting and milestones.

On 2026-09-14, Robert Barrow, Chief Executive Officer of Definium Therapeutics, Inc., acquired 750,000 common shares at a stated price of $0.00 per share as the third tranche of a performance share unit award originally granted on March 12, 2025. These shares are not yet fully earned; they remain subject to vesting conditions tied to Mr. Barrow’s continued employment through March 12, 2028 and the achievement of specified clinical and regulatory milestones under the Performance Share Unit Award Agreement. Following this award-related acquisition, Mr. Barrow’s direct beneficial ownership increased to 2,244,640 common shares, representing a substantial equity-based compensation position aligned with long-term performance rather than an open-market purchase.

Filing Facts

CIK

1813814

Ticker

DFTX

Form

4

Source Type

fda

Accession

0001193125-26-389887

Alert Tier

6